Lilly(Eli) & Co
NYSE:LLY 4:00:00 PM EDT
Earnings Announcements
Lilly Announces Agreement To Acquire Prevail Therapeutics
Published: 12/15/2020 11:46 GMT
Lilly(Eli) & Co (LLY) - Lilly Announces Agreement to Acquire Prevail Therapeutics.
Eli Lilly - Lilly to Acquire Prevail for $22.50 per Share in Cash Payable at Closing Plus One Non-tradable Cvr Worth Up to $4 per Share in Cash.
Eli Lilly - Deal for Total Consideration of Up to $26.50 per Share in Cash.
Eli Lilly - Cvr is Payable Upon First Regulatory Approval of a Product From Prevail's Pipeline.
Eli Lilly - Transaction is Not Subject to Any Financing Condition.
Eli Lilly - Upon Closing, Impact of Deal Will Be Reflected in Lilly's 2021 GAAP Financial Results.
Eli Lilly - Lilly to Acquire Prevail for $22.50 per Share in Cash Payable at Closing Plus One Non-tradable Cvr Worth Up to $4 per Share in Cash.
Eli Lilly - Deal for Total Consideration of Up to $26.50 per Share in Cash.
Eli Lilly - Cvr is Payable Upon First Regulatory Approval of a Product From Prevail's Pipeline.
Eli Lilly - Transaction is Not Subject to Any Financing Condition.
Eli Lilly - Upon Closing, Impact of Deal Will Be Reflected in Lilly's 2021 GAAP Financial Results.
Revenue is expected to be $6.85 Billion
Adjusted EPS is expected to be $1.76
Next Quarter Revenue Guidance is expected to be $7.3 Billion
Next Quarter EPS Guidance is expected to be $1.86
More details on our Analysts Page.
Adjusted EPS is expected to be $1.76
Next Quarter Revenue Guidance is expected to be $7.3 Billion
Next Quarter EPS Guidance is expected to be $1.86
More details on our Analysts Page.